Research Analysts Issue Forecasts for Kura Oncology Q1 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Kura Oncology in a research report issued to clients and investors on Wednesday, February 26th. Brookline Capital Management analyst L. Cann expects that the company will post earnings per share of ($0.52) for the quarter. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology's Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.44) EPS, FY2026 earnings at $0.84 EPS, FY2027 earnings at $3.04 EPS, FY2028 earnings at $5.85 EPS and FY2029 earnings at $12.11 EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million.

Several other equities research analysts have also commented on the stock. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Bank of America reduced their price target on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a report on Friday, November 22nd. StockNews.com upgraded Kura Oncology from a "sell" rating to a "hold" rating in a research report on Thursday, February 27th. JMP Securities restated a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $27.13.

Remove Ads

Kura Oncology Price Performance

Shares of NASDAQ:KURA traded up $0.08 during trading on Friday, reaching $7.33. 1,574,644 shares of the company's stock traded hands, compared to its average volume of 1,599,634. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company has a 50-day simple moving average of $8.10 and a 200-day simple moving average of $13.64. The firm has a market cap of $570.01 million, a PE ratio of -3.11 and a beta of 0.85.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of KURA. China Universal Asset Management Co. Ltd. increased its position in shares of Kura Oncology by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company's stock worth $288,000 after purchasing an additional 5,788 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Kura Oncology by 21.9% in the third quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company's stock valued at $924,000 after purchasing an additional 8,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Kura Oncology by 35.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company's stock worth $579,000 after purchasing an additional 7,722 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Kura Oncology in the 3rd quarter valued at about $298,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Kura Oncology by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company's stock valued at $12,212,000 after buying an additional 14,106 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.